Geurts, Sandra M. E. http://orcid.org/0000-0002-4265-9968
Ibragimova, Khava I. E.
Ding, Nan
Meegdes, Marissa
Erdkamp, Frans
Heijns, Joan B.
Tol, Jolien
Vriens, Birgit E. P. J.
Dercksen, Marcus W.
Aaldering, Kirsten N. A.
Pepels, Manon J. A. E.
van de Winkel, Linda
Peters, Natascha A. J. B.
van de Wouw, Agnes J.
Maaskant, Sabrina A. J. G.
Teeuwen-Dedroog, Nathalie J. A.
van Nijnatten, Thiemo J. A.
de Boer, Maaike
Tjan-Heijnen, Vivianne C. G.
Funding for this research was provided by:
Netherlands Organization for Health Research and Development (80-82500-98-8003)
Novartis
Roche
Pfizer
Eli Lilly and Company
Gilead Sciences
AstraZeneca
Article History
Received: 4 September 2023
Accepted: 14 December 2023
First Online: 21 February 2024
Declarations
:
: Financial interests: SG reports institutional grants from Novartis BV, Roche, Pfizer, Eli Lilly, Daiichi Sankyo, Gilead and AstraZeneca, and personal fees from AstraZeneca. KI reports institutional grants from Novartis BV, Roche, Pfizer, Eli Lilly and Daiichi Sankyo. MM reports institutional grants from Novartis BV, Roche, Pfizer, Eli Lilly, Daiichi Sankyo and Gilead. NTD reports institutional grants from Novartis BV, Roche, Pfizer, Eli Lilly, Daiichi Sankyo, Gilead and AstraZeneca. MdB reports institutional grants from Novartis BV, Roche, Pfizer, Eli Lilly, Daiichi Sankyo, Gilead and AstraZeneca. VTH reports institutional grants and personal fees from Roche, Novartis, Pfizer, and Eli Lilly, personal fees from Accord Healthcare, institutional grants from AstraZeneca, Eisai, Daiichi Sankyo and Gilead. All remaining authors have no relevant financial or non-financial interests to declared. The authors have no relevant non-financial interests to disclose.
: Due to the observational character of this study, the need for informed consent was waived by the Medical Research Ethics Committee of Maastricht University Medical Center (METC 15–4–239). The study was performed in accordance with the Declaration of Helsinki.